


Receipt



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger
Judith U. Kim
Timothy J. Shea, Jr.

Patrick E. Garrett
Jeffery T. Helvey*
Heidi L. Kraus
Crystal D. Sayles
Edward W. Yee
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II*
Eldora Ellison Floyd
W. Russell Swindell
Thomas C. Fiala
Brian J. Del Buono*
Virgil Lee Beaton*
Reginald D. Lucas*

Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham*
Christine M. Lhulier
Rae Lynn Prengaman*
Jane Shershenovich*
Lawrence J. Carroll*
George S. Bardmesser

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III

Registered Patent Agents
Karen R. Markowicz
Andrea J. Kamage

Nancy J. Leith
Joseph M. Conrad III
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Jason D. Eisenberg
Alicia M. Choi

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas

April 17, 2002

Commissioner for Patents
Washington, D.C. 20231

WRITER'S DIRECT NUMBER:
(202) 371-2625
INTERNET ADDRESS:
ESTEFFE@SKGF.COM

Group Art Unit 1631

Re: U.S. Utility Patent Appl. No. 10/028,780; Filed: December 28, 2001
For: **Antibodies Directed to ELL2, a New Member of an ELL Family of
RNA Polymerase II Elongation Factors**

Inventors: Duan *et al.*
Our Ref: 1488.0880003/EKS/PSC

RECEIVED

MAY 03 2002

Sir:

TECH CENTER 1600/2900

Transmitted herewith for appropriate action are the following documents:


1. Request for Corrected Official Filing Receipt;
2. A photocopy of the instant Official Filing Receipt with corrections noted in red; and
3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

EKS/PSC/lam
Enclosures

SKGF_DC1:3381.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Duan *et al.*

Appl. No. 10/028,780

Filed: December 28, 2001

For: **Antibodies Directed to ELL2, a New
Member of an ELL Family of RNA
Polymerase II Elongation Factors**



Confirmation No. 6418

Art Unit: 1631

Examiner: *To be assigned*

Atty. Docket: 1488.0880003/EKS/PSC

RECEIVED
MAY 03 2002

Request for Corrected Official Filing Receipt TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Attn: Office of Initial Patent
Examination's Customer
Service Center

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:

In the Title section, please insert at the beginning of line 1, --Antibodies directed to--.

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 4/17/02
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/028,780	12/28/2001	1631	2072	1488.0880003	7	80	6

CONFIRMATION NO. 6418

28730

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
SUITE 600
WASHINGTON, DC 20005-3934



FILING RECEIPT



10800000007794871*

RECEIVED

MAY 03 2002

Date Mailed: 04/04/2002

TECH CENTER 1600/2900

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

D. Roxanne Duan, Bethesda, MD;
Ali Shilatifard, St. Louis, MO;
Joan W. Conaway, Oklahoma City, OK;
Ronald C. Conaway, Oklahoma City, OK;

Assignment For Published Patent Application

Human Genome Sciences, Inc.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/362,871 07/29/1999
WHICH IS A DIV OF 09/026,343 02/19/1998 PAT 6,008,018
WHICH CLAIMS BENEFIT OF 60/038,447 02/19/1997


Foreign Applications

If Required, Foreign Filing License Granted 04/03/2002

Projected Publication Date: 07/11/2002

Non-Publication Request: No

Early Publication Request: No



Title

Antibodies directed to

ELL2, a new member of an ELL family of RNA polymerase II elongation factors

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/028,780	12/28/2001	D. Roxanne Duan	1488.0880003

FILE COPY

CONFIRMATION NO. 6418

28730
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
SUITE 600
WASHINGTON, DC 20005-3934



OC000000007971991

Date Mailed: 04/29/2002

RESPONSE TO REQUEST FOR CORRECTED FILING RECEIPT

Title of Invention

In response to your request for a corrected Filing Receipt, the Office cannot comply with your request because:

- ☐ The articles such as "a," "an," and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- ☐ The words "new," "improved," "improvement of," "improvement in", or "improvement relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement. See MPEP 606.
- ☐ The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- ☐ Superscript and subscript are not possible. These characters will appear on the same line.
- ☐ The title appears on the filing receipt in sentence case for publication in the Annual Index of Patents.
- ☒ The title of the invention was captured as provided by applicant on the first page of the specification. An amendment is needed to make this change.

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

Neyla Kuroyan

Customer Service Center
Office of Initial Patent Examination
(703) 308-1202